Sertraline and Alprazolam in the Treatment of Panic Disorder

A compared, 12 week, placebo controlled study, with fixed dose, outpatient study of patients diagnosed with panic disorder with and without agoraphobia according to ICD-10, was conducted to evaluate the efficacy and safety of sertraline and alprazolam. The study included 40 patients, divided in two...

Full description

Bibliographic Details
Main Authors: Saida Fišeković, Svjetlana Loga-Zec
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2005-05-01
Series:Bosnian Journal of Basic Medical Sciences
Subjects:
Online Access:http://www.bjbms.org/ojs/index.php/bjbms/article/view/3292
id doaj-2efebd5d296448a7834f197b24e83cb5
record_format Article
spelling doaj-2efebd5d296448a7834f197b24e83cb52020-11-25T00:28:51ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBosnian Journal of Basic Medical Sciences1512-86011840-48122005-05-015210.17305/bjbms.2005.3292782Sertraline and Alprazolam in the Treatment of Panic DisorderSaida Fišeković0Svjetlana Loga-Zec1Psychiatric Clinic, University Clinics CenterInstitute for Pharmacology, Clinical Pharmacology and Toxicology, School of MedicineA compared, 12 week, placebo controlled study, with fixed dose, outpatient study of patients diagnosed with panic disorder with and without agoraphobia according to ICD-10, was conducted to evaluate the efficacy and safety of sertraline and alprazolam. The study included 40 patients, divided in two groups. We evaluated number of ICD-10-defined panic attacks, agoraphobia and anticipatory anxiety. All patients were aged 18 year and older and were randomized to either sertraline or alprazolam. Sertraline applied in fixed doses of 20 mg/day and alprazolam in doses 1-1,5 mg/day significantly reduced the frequency of panic attacks in panic disorder patients, reduced symptoms of agoraphobia and anticipatory anxietyhttp://www.bjbms.org/ojs/index.php/bjbms/article/view/3292panic disordersSSRIbenzodiazepine
collection DOAJ
language English
format Article
sources DOAJ
author Saida Fišeković
Svjetlana Loga-Zec
spellingShingle Saida Fišeković
Svjetlana Loga-Zec
Sertraline and Alprazolam in the Treatment of Panic Disorder
Bosnian Journal of Basic Medical Sciences
panic disorders
SSRI
benzodiazepine
author_facet Saida Fišeković
Svjetlana Loga-Zec
author_sort Saida Fišeković
title Sertraline and Alprazolam in the Treatment of Panic Disorder
title_short Sertraline and Alprazolam in the Treatment of Panic Disorder
title_full Sertraline and Alprazolam in the Treatment of Panic Disorder
title_fullStr Sertraline and Alprazolam in the Treatment of Panic Disorder
title_full_unstemmed Sertraline and Alprazolam in the Treatment of Panic Disorder
title_sort sertraline and alprazolam in the treatment of panic disorder
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
series Bosnian Journal of Basic Medical Sciences
issn 1512-8601
1840-4812
publishDate 2005-05-01
description A compared, 12 week, placebo controlled study, with fixed dose, outpatient study of patients diagnosed with panic disorder with and without agoraphobia according to ICD-10, was conducted to evaluate the efficacy and safety of sertraline and alprazolam. The study included 40 patients, divided in two groups. We evaluated number of ICD-10-defined panic attacks, agoraphobia and anticipatory anxiety. All patients were aged 18 year and older and were randomized to either sertraline or alprazolam. Sertraline applied in fixed doses of 20 mg/day and alprazolam in doses 1-1,5 mg/day significantly reduced the frequency of panic attacks in panic disorder patients, reduced symptoms of agoraphobia and anticipatory anxiety
topic panic disorders
SSRI
benzodiazepine
url http://www.bjbms.org/ojs/index.php/bjbms/article/view/3292
work_keys_str_mv AT saidafisekovic sertralineandalprazolaminthetreatmentofpanicdisorder
AT svjetlanalogazec sertralineandalprazolaminthetreatmentofpanicdisorder
_version_ 1725334025923461120